MedTrace Logo

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

NCT00042302 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 540

Last updated 2012-05-23

No results posted yet for this study

Summary

To determine whether tariquidar + combined first-line chemotherapy of paclitaxel/carboplatin in patients with Stage IIIb/IV NSCLC will, with an acceptable safety profile, significantly improve overall survival compared with placebo + paclitaxel/carboplatin. To compare the effects of tariquidar/paclitaxel/carboplatin with placebo/paclitaxel/carboplatin on tumor response, time to disease progression, performance status, symptom progression, and quality of life in patients with Stage IIIb/IV NSCLC.

Conditions

  • Stage IIIb Non-small Cell Lung Cancer
  • Stage IV Non-small Cell Lung Cancer

Interventions

PROCEDURE

Chemotherapy

DRUG

tariquidar + paclitaxel/carboplatin

DRUG

placebo + paclitaxel/carboplatin

Sponsors & Collaborators

  • QLT Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-06-30
Primary Completion
2003-07-31
Completion
2003-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00042302 on ClinicalTrials.gov